bioihbjkbjnl/mcl2 huggingface dataset:
Travelling in Patients With Sleep Related Breathing Disorders
Condition: Travel, Sleep Related Disorder
Study type: Observational

Summary: 
      One questionnaire has been configured to ask therapy naive and treated patients about their
      travel activities. Travel activities include private and professional traveling. Another
      questionnaire collects medical information.
    

Detailed description: 
      Including a German sleep committee a new questionnaire has been created to ask patients about
      their travel Habits. Only travels over a onenightstay were of interest. All detailed
      Information about the Destination has been asked. A Special Point of interest were the
      Impacts of traveling. For each Patient a doctor completed the medical history including sleep
      related breathing disorder and relevant medical conditions e.g. orthopedic Impacts.
    

Intervention name(s): questionnaire for travel habits
Intervention type(s): Other
Intervention description(s): questionnaire has been used to collect information about travelling
Time perspective: Prospective
Sampling method: Probability Sample
Study population: 
        patients with sleep related breathing disorder
Follow-up Investigation of Efficacy of Ragweed MATAMPL,and Placebo in Patients With Ragweed-induced Seasonal Allergic Rhinitis
Condition: Type I Hypersensitivity
MeSH terms: Rhinitis; Rhinitis, Allergic; Rhinitis, Allergic, Seasonal; Hypersensitivity; Hypersensitivity, Immediate
Study type: Interventional
Phase: Phase 2

Summary: 
      Ragweed MATAMPL has been developed to provide pre-seasonal specific immunotherapy for
      patients with hypersensitivity to ragweed pollen (hay fever). This novel formulation is
      designed to provide a vaccine that will be efficacious with only four escalating dose
      injections administered before the start of the pollen season. In this Follow-up Study the
      Efficacy will be assessed by exposing allergic subjects to Ragweed pollen in an environmental
      exposure chamber EEC. Patient symptomatic response to pollen and patient quality of life in
      the EEC will be determined. Patients who previously completed two EEC portions of study
      Ragweed MATAMPL 204 and who had been treated with either Ragweed MATA MPL or Placebo before
      the 2005 ragweed season will be enrolled.
    


Intervention name(s): Ragweed MATAMPL
Intervention type(s): Biological
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single
Primary purpose: Treatment
Keywords: Allergy; Specific Immunotherapy; Ragweed; Environmental Exposure Chamber
The Efficacy of Doxazosin for Cocaine Users
Condition: Cocaine Dependence
MeSH terms: Cocaine-Related Disorders
Study type: Interventional
Phase: Phase 1

Summary: 
      Doxazosin, an alpha 1-adrenergic receptor, may play an important role in cocaine addiction in
      humans. This study will evaluate the effectiveness of doxazosin in preventing drug relapse
      among cocaine dependent participants.
    

Detailed description: 
      The NE system, especially the alpha 1-adrenergic receptor, may play an important role in
      cocaine addiction in humans. The results of this study will provide medical safety data on
      the duration of the induction schedule that will be optimal for attaining our target dose of
      8 mg doxazosin daily and will guide future pharmacotherapy trials using Doxazosin or related
      alpha 1 receptor antagonists for cocaine addiction.

      This 17-week double-blind, placebo controlled clinical trial includes a 13 week medication
      trial (weeks 1-13) and up to 4 week washout period(weeks 14-17). Qualifying subjects will be
      randomized to receive Doxazosin 8 mg/day, or placebo during the study participation.

      Medication induction will occur at a rate of 2mg/week until 8mg/day target dose is achieved
      as follows:

        1. Dox-Fast Group: Defined as participants reaching the target dose after a 4-week
           titration period. Participants will be stabilized on doxazosin or placebo over weeks
           4-13 (for Dox-Fast group)

        2. Dox-Slow Group: Defined as participants reaching the target dose after an 8-week
           titration period. Participants will be stabilized on doxazosin or placebo over weeks
           8-13 (for Dox-Slow group)

      Both groups will be tapered off doxazosin or placebo over study weeks 14-17.
    

Intervention name(s): Doxazosin; Placebo
Intervention type(s): Drug; Other
Intervention description(s): Medication induction occurred at a rate of 2mg/week until 8mg/day target dose was achieved as follows:
Dox-Fast Group: Defined as participants reaching the target dose after a 4-week titration period. Participants were stabilized on doxazosin or placebo over weeks 4-13 (for Dox-Fast group)
Dox-Slow Group: Defined as participants reaching the target dose after an 8-week titration period. Participants were stabilized on doxazosin or placebo over weeks 8-13 (for Dox-Slow group)
Both doxazosin groups will be tapered off doxazosin or placebo over study weeks 14-17.; Participants will be administered a sugar pill to mimic the doxazosin active medication with administration being the same as the active medication.
Other intervention name(s): Cardura (Doxazosin Mesylate); sugarpills ( Capsules)
Intervention MeSH terms: Doxazosin
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Cocaine Dependence; Substance Related Disorders
Influence of Freeze Dried Strawberry Consumption on Gut Microbiota and Cardiovascular Health.
Condition: Microbial Colonization; Cardiovascular Diseases; Obesity
MeSH terms: Communicable Diseases; Infections; Cardiovascular Diseases
Study type: Interventional

Summary: 
      This proposal seeks to build upon studies, including ours, on the favorable effects of
      California strawberries on vascular health. Freeze dried strawberry powder (FDSP) contains a
      number of nutrients that may have beneficial effects on plasma lipids and vascular function,
      as well as on the composition of the gut microbiota; changes in the gut microbiota can in
      turn have secondary positive effects on the vascular system as well as on other physiological
      functions that are important determinants of health and disease. The proposed project will
      seek to determine the influence of short-term FDSP intake on the gut microbiota composition,
      and select microbial-derived metabolites from stool, serum and urine, and their relationship
      to microvascular function. Secondary outcomes will include the influence of the FDSP on
      circulating levels of nitrate and nitrite and trimethylamine oxide (TMAO) as markers of
      vascular health that are influenced by both dietary intake and the oral and gut microflora,
      with blood pressure as an additional vascular outcome.
    

Detailed description: 
      A randomized, double-blind, controlled crossover design will compare the short-term (two and
      four week) response to FDSP intake compared to an isocaloric control powder in overweight and
      obese adults. Twenty overweight or obese male or postmenopausal females (40-65 years of age)
      will be randomized to consume 39 g of FDSP or a control powder for four weeks in a crossover
      design with a four week washout period. Changes in stool microbial communities and microbial
      metabolites will be assessed, and examined for their potential influence on microvascular
      function.
    

Intervention name(s): Freeze Dried Strawberry Powder; Isocaloric powder
Intervention type(s): Other; Other
Intervention description(s): Study participants will be randomized to receive either the freeze dried strawberry powder or the control powder first. They will be instructed to consume 39g of the powder, mixed in water, every day for 4 weeks.; Isocaloric powder
Allocation: Randomized
Intervention model: Crossover Assignment
Intervention model description: Randomized, double-blind, controlled crossover dietary intervention trial
Masking: Triple (Participant, Care Provider, Investigator)
Primary purpose: Basic Science
A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese
Condition: Healthy Volunteers; Diabetes Mellitus, Type 2
MeSH terms: Diabetes Mellitus, Type 2
Study type: Interventional
Phase: Phase 1

Summary: 
      This study looks at the way a new medicine tablet called semaglutide moves in and throughout
      the body over time. It will also look at if the medicine is safe and the body can accept it.
      The new medicine is planned to treat diabetes. The aim of the study is to see how semaglutide
      tablets work in healthy people who are Chinese. Participants will either get oral semaglutide
      tablets or placebo (dummy) tablets - which treatment is decided by chance. The tablet form of
      semaglutide is a new medicine that cannot be prescribed. Doctors can prescribe semaglutide as
      an injection only. It is for the treatment of diabetes in some countries. Participants will
      get 1 tablet per day for 12 weeks (84 days). Participants will get 1 tablet a day to take
      with up to half a glass of water (maximum 120 mL). Participants must take the tablet first
      thing in the morning on an empty stomach (water is allowed until 2 hours before taking the
      tablet). After taking the tablet, participants must not eat or drink anything for at least 30
      minutes. After 30 minutes, they can have their first meal of the day and take any other
      medicines they may need, such as birth control tablets, routine vitamins and use of
      paracetamol at times.
    


Intervention name(s): Oral semaglutide; Placebo
Intervention type(s): Drug; Drug
Intervention description(s): Semaglutide tablets once daily as follows: 3 mg for the first treatment period (day 1-28), followed by 7 mg in the second treatment period (day 29-56), followed by 14 mg in the third treatment period (day 57-84); Placebo tablets once daily throughout the treatment period (day 1 to 84)
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Anterior Prolift Versus Posterior Prolift for Pelvic Floor Prolapse
Condition: Pelvic Floor Prolapse
MeSH terms: Prolapse
Study type: Observational

Summary: 
      Women who had surgery for pelvic floor prolapse underwent surgery by anterior Prolift or
      Posterior prolift at least a year after the surgery.

      The data from the charts and from telephone conversations with the patients will be entered
      to a database. Physical examination data will also be incorporated.
    


Observational model: Case-Control
Time perspective: Retrospective
Sampling method: Non-Probability Sample
Study population: 
        Women with pelvic floor prolapse who underwent surgery with Prolift
Characterization of T-Cell Response in Participants Previously Treated With JNJ-54861911 (Atabecestat)
Condition: Alzheimer Disease
MeSH terms: Alzheimer Disease
Study type: Interventional
Phase: Early Phase 1

Summary: 
      The purpose of this study is to determine T-cell mediated inflammatory immune response in
      some participants previously exposed to atabecestat.
    

Detailed description: 
      This is an exploratory Phase 0 study in participants who previously participated in studies
      (54861911ALZ2002 [NCT02260674], 54861911ALZ2003 [NCT02569398], or 54861911ALZ2004
      [NCT02406027]) with atabecestat. In this study, participants will only have blood drawn. The
      primary hypotheses for this study is that adverse event of elevated liver enzymes observed in
      some participants is caused by a T-cell dependent inflammatory response. Participants will be
      monitored for adverse events and will be called 1 day after the blood draw to assess for any
      adverse events.
    

Intervention name(s): Atabecestat
Intervention type(s): Drug
Intervention description(s): Blood samples will be collected from participants previously treated with atabecestat.
Other intervention name(s): JNJ-54861911
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Other
Dual Site-dual Channel Non-invasive Brain Stimulation for Motor Function in Stroke Patients
Condition: Stroke
MeSH terms: Stroke
Study type: Interventional

Summary: 
      The aim of this study is to investigate the effect of dual site-dual channel non-invasive
      brain stimulation for recovery of motor function in post stroke patients. Simultaneous dual
      site-dual channel stimulation was applied by using two sets of transcranial direct current
      stimulation devices. All subjects will go through three conditions of transcranial direct
      current stimulation with for 30 minutes. Three conditions are 1) Dual stimulation 1: i)
      anodal stimulation on ipsilesional primary motor cortex and cathodal stimulation on
      contralesional primary motor cortex, ii) anodal stimulation on ipsilesional premotor cortex
      and cathodal stimulation on contralesional supraorbital area. 2) Dual stimulation 2: i)
      anodal stimulation on ipsilesional primary motor cortex and cathodal stimulation on
      contralesional primary motor cortex, ii) anodal stimulation on ipsilesional anterior
      intraparietal sulcus and cathodal stimulation on contralesional supraorbital area. 3) Single
      stimulation: anodal stimulation on ipsilesional primary motor cortex and cathodal stimulation
      on contralesional primary motor cortex.
    


Intervention name(s): M1 stimulation; PMC stimulation; aIPS stimulation; hand motor task
Intervention type(s): Device; Device; Device; Behavioral
Intervention description(s): stimulating primary motor cortex with anodal transcranial direct current stimulation; stimulating premotor cortex with anodal transcranial direct current stimulation; stimulating anterior intraparietal sulcus with anodal transcranial direct current stimulation; hand motor task for 30 minutes during transcranial direct current stimulation
Other intervention name(s): primary motor cortex anodal stimulation; premotor cortex anodal stimulation
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary purpose: Treatment
Keywords: transcranial direct current stimulation; dual stimulation
Intranasal Oxytocin and Social Cognition, Implicit Preferences and Craving in Alcohol Drinkers
Condition: AOD Use, Abuse, and Dependence
Study type: Interventional
Phase: Phase 4

Summary: 
      This is a randomized, placebo controlled, double blind crossover study of the effects of
      intranasal oxytocin on social cognition, implicit preferences and craving in moderate to
      heavy social alcohol drinkers.
    

Detailed description: 
      Impaired social functioning is an important feature of substance use disorders. Social
      deficits are a risk factor for developing substance use disorders as well as a consequence of
      substance abuse. Improved social functioning is also a key goal of effective substance abuse
      treatments. While treatment of disrupted social networks is a mainstay of psychosocial
      substance abuse treatments, there are currently no pharmacological interventions aimed at
      improving social functioning in individuals with substance use disorders. Oxytocin
      administration may shift preference from substance related cues to social cues and may
      decrease subjective craving for alcohol.

      The specific aims are:

        1. To examine the effects of intranasal oxytocin administration on social cognition in
           moderate to heavy social alcohol drinkers.

        2. To examine the effects of intranasal oxytocin administration on alcohol craving.

        3. To examine the effects of intranasal oxytocin administration on implicit preferences for
           drug-related and social stimuli in moderate to heavy social alcohol drinkers.
    

Intervention name(s): Oxytocin; Placebo
Intervention type(s): Drug; Drug
Intervention description(s): Intranasal oxytocin; Intranasal placebo
Other intervention name(s): Syntocinon
Intervention MeSH terms: Oxytocin
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Benefits of a Higher Protein, 'Egg-cellent' Breakfast in the Classroom
Condition: Breakfast; Obesity; Mood; Eating Behavior
MeSH terms: Obesity
Study type: Interventional

Summary: 
      This study will test whether whether the implementation of and Egg-cellent 'Breakfast in the
      Classroom' improves school breakfast participation and breakfast consumption in middle school
      adolescents; whether the implementation of 'Breakfast in the Classroom' improves appetite
      control, mood, cognitive performance, and unhealthy snacking behavior in middle school
      adolescents when compared to a traditional school breakfast program.
    

Detailed description: 
      The investigators propose an 4-week cross-over design breakfast study in children enrolled in
      6-8th grade within the Center School District in the Kansas City, Missouri. This school will
      begin their 'Breakfast in the Classroom' program on March 26, 2018. Prior to the start of
      'Breakfast in the Classroom', baseline data will be collected on the students who wish to
      participate in the study. Baseline data includes anthropometric assessments; demographics;
      current eating habits; cognitive performance; appetite; and mood. Following baseline, the
      students will be provided a breakfast that meets all the requirements for a reimbursable
      school breakfast with the addition of two eggs for 3-weeks: At 4 weeks (3 weeks after
      initiation of the program), the study participants will complete a similar outcomes to those
      completed at baseline.
    

Intervention name(s): 'Egg-cellent' Breakfast in the Classroom; Breakfast in the Classroom
Intervention type(s): Other; Other
Intervention description(s): Includes the additional 2 eggs per day; Receives the standard meal for Breakfast in the Classroom
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Other
Keywords: Breakfast; Obesity; Mood; Eating Behavior; Cognitive Function
Aerosol Delivery in Different Types of Nebulizers
Condition: Asthma
Study type: Interventional

Summary: 
      Background: Nebulizers design influences efficiency of aerosol delivery. Performance of
      nebulizers is commonly tested by breathing simulators with static parameters. However,
      breathing patterns vary in adults.

      Objectives: The purpose of this study was to evaluate drug deposition of different types of
      nebulizers testing with breathing patterns of healthy subjects.
    

Detailed description: 
      Material and Methods

      The study was approved by Chang Gung Memorial Foundation Institutional Review Broad. Ten
      healthy subjects, aged 20.6±0.5 years, were recruited. Four nebulizers:

        1. a constant jet nebulizer (Neb-easy, Galemed Corp., Taiwan);

        2. a breath enhanced nebulizer (Pari LC plus, Pari Inc., Germany);

        3. a manual-actuated nebulizer (A-T Neb, Atlantean Corporation, Taiwan); and

        4. a breath-actuated nebulizer (AeroElipes, Trudell Medical Inc, Canada) were evaluated.
    

Intervention name(s): Constant jet nebulizer; Breath enhanced nebulizer; Manual-actuated nebulizer; Breath-actuated nebulizer
Intervention type(s): Device; Device; Device; Device
Intervention description(s): A constant jet nebulizer (Neb-easy, Galemed Corp., Taiwan) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.; A breath enhanced nebulizer (Pari LC plus, Pari Inc., Germany) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.; A manual-actuated nebulizer (A-T Neb, Atlantean Corporation, Taiwan) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.; A breath-actuated nebulizer (AeroElipes, Trudell Medical Inc, Canada) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Health Services Research
Pro-inflammatory Cytokines in Facioscapulohumeral Muscular Dystrophy (CYTOKINE-FSH)
Condition: Muscular Dystrophies
MeSH terms: Muscular Dystrophies; Muscular Dystrophy, Facioscapulohumeral
Study type: Interventional

Summary: 
      The facial-glenohumeral muscular dystrophy type 1 (DMFSH1) is characterized by a selective
      and asymmetrical involvement of the facial muscles, the shoulder girdle and the anterolateral
      lodge legs. Genetically, the disease is transmitted in an autosomal dominant manner and is
      caused by a pathogen contraction of repeat units (UR) say D4Z4 localized to the telomeric
      portion of chromosome 4qA. The loss of UR causes hypomethylation of DNA and chromatin
      relaxation of the region that lead to inappropriate expression of DUX4 retrogene highly
      toxic. The inappropriate expression induces a T cell reaction inflammatory response that
      participate and increase muscle damage. In favor of this hypothesis, several muscle MRI
      studies have shown that atrophy and fibro-adipose degeneration (hyper signal in T1) were
      preceded by the appearance of muscle inflammation (hyper signal T2STIR) confirmed on
      histologically and dysregulation of genes involved in adaptive and innate immunity.
      scientific hypothesis and potential benefits: the investigateur hypothesize that in patients
      of DMFSH1, the immune system cells may participate in the pathophysiology of the disease
      through changes in serum secretion of one or more cytokines and / or a modification of the
      response of inflammatory cells in some cell damage stimuli. Design: this is a single-center
      pilot study, interventional. In this study, the investigator will assay the serum cytokines
      and changes in peripheral blood cells of the expression of cytokines in response to some
      stimuli in 20 patients with Type 1 DMFSH genetically confirmed at an intermediate stage of
      clinical disease (kept walking, but at least one muscle of lower limbs reached) and compare
      with controls from the CYTOKINAGE study. The investigator will also carry patients clinical
      testing (MMT sum score) and functional (6minute test march MFM) and a MRI not injected whole
      body (T1 sequences + and T2STIR) to study the relationship between these parameters and
      secretion cytokines or serum in response to certain stimuli Main objective: to compare serum
      levels of IL-6 in patients with DMFSH and controls.
    


Intervention name(s): cytokines dosage; test of walk; Manual muscular test; Motrice fonction mesurement
Intervention type(s): Other; Procedure; Procedure; Procedure
Intervention description(s): Mesure of cytokines concentration in serum; patient must walk during 6 minutes on a flat surface; test performed to evaluate the patient muscular weakness; scale allowing the evaluation of patient posture and upper body movements
Other intervention name(s): biological analysis
Intervention model: Single Group Assignment
Intervention model description: Interventional pilot study
Masking: None (Open Label)
Primary purpose: Other